W. Thorpe McKenzie filed Amendment No. 9 to Schedule 13G with the SEC on November 18, 2026, disclosing beneficial ownership of 2,572,735 common shares of XBiotech Inc., representing 8.4% of the class as of November 16, 2026.
Key Highlights
- Total beneficial ownership: McKenzie reported aggregate beneficial ownership of 2,572,735 shares of XBiotech Inc. common stock.
- Percent of class: The 2,572,735 shares represent 8.4% of the class, according to the filing.
- Sole voting and dispositive power: McKenzie holds sole voting and sole dispositive power over 2,505,987 shares.
- Shared voting and dispositive power: An additional 66,748 shares are held by the McKenzie Foundation, over which shared voting and dispositive power is reported.
- Foundation disclaimer: The filing states McKenzie "disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."
- Shares outstanding basis: The percentage is calculated using 30,487,731 shares outstanding as of November 17, 2026, plus 237,500 shares issuable upon exercise of stock options held by McKenzie.
McKenzie's XBiotech Ownership Details as of November 2026
According to the filing, W. Thorpe McKenzie, a United States citizen based in Chattanooga, Tennessee, submitted Amendment No. 9 to his Schedule 13G regarding common shares of XBiotech Inc. (NASDAQ:XBIT), headquartered at 5217 Winnebago Ln, Austin, TX 78744. The event triggering the filing occurred on November 16, 2026, and the statement was signed and dated November 18, 2026.
The filing discloses that McKenzie's aggregate beneficial ownership of 2,572,735 shares includes shares underlying stock options, specifically options that are "immediately exercisable within 60 days of November 17, 2026," as stated in the filing. Of the total, 2,505,987 shares are held with sole voting and sole dispositive power, while 66,748 shares are attributed to the McKenzie Foundation, over which McKenzie reports shared voting and shared dispositive power.
The 8.4% ownership percentage is based on a denominator combining 30,487,731 shares outstanding as of November 17, 2026, and 237,500 shares issuable upon McKenzie's exercise of stock options, as described in the filing. The filing classifies McKenzie as an individual (type "IN") and was filed under Rule 13d-1(b) of the Securities Exchange Act of 1934.
What Was Disclosed
W. Thorpe McKenzie filed Amendment No. 9 to Schedule 13G reporting beneficial ownership of 2,572,735 XBiotech Inc. common shares, equal to 8.4% of the class, including 66,748 shares held by the McKenzie Foundation as of November 16, 2026.



Please wait processing your request...